Bank of New York Mellon Corp Sells 3,609 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Bank of New York Mellon Corp lessened its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 3.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 101,358 shares of the company’s stock after selling 3,609 shares during the quarter. Bank of New York Mellon Corp’s holdings in Entrada Therapeutics were worth $1,752,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in Entrada Therapeutics by 8.8% in the 3rd quarter. Geode Capital Management LLC now owns 576,451 shares of the company’s stock worth $9,214,000 after acquiring an additional 46,512 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Entrada Therapeutics by 132.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 138,605 shares of the company’s stock valued at $2,215,000 after acquiring an additional 78,953 shares in the last quarter. Barclays PLC boosted its position in shares of Entrada Therapeutics by 210.6% during the 3rd quarter. Barclays PLC now owns 45,110 shares of the company’s stock valued at $720,000 after acquiring an additional 30,585 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Entrada Therapeutics by 34.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock valued at $226,000 after buying an additional 3,644 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA acquired a new position in Entrada Therapeutics in the third quarter valued at about $1,109,000. Institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Stock Up 0.8 %

Entrada Therapeutics stock opened at $10.49 on Friday. The stock has a market capitalization of $394.37 million, a PE ratio of 6.60 and a beta of -0.14. Entrada Therapeutics, Inc. has a twelve month low of $10.15 and a twelve month high of $21.79. The company has a 50 day moving average of $12.25 and a 200-day moving average of $15.60.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.66) by $0.69. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The business had revenue of $12.25 million during the quarter, compared to analysts’ expectations of $11.95 million. Equities analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on TRDA shares. Roth Mkm started coverage on shares of Entrada Therapeutics in a research report on Thursday, December 5th. They issued a “buy” rating and a $29.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Tuesday, February 25th. Finally, Roth Capital raised shares of Entrada Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th.

Entrada Therapeutics Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.